GlassScriptPhysician profile
Reagan Garber
NPI 1033791322
$2,166.66
in general payments reported to CMS, 2019-2025
18 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $528 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $313.04 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $289.49 | 2024-2025 | |
| Novo Nordisk INC | $258.05 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $210.86 | 2024-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $196.92 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $173.13 | 2024-2025 | Rexulti |
| Pfizer INC. | $162.93 | 2024-2025 | |
| Lilly USA, LLC | $136.38 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Antares Pharma, INC. | $89.35 | 2024-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.40 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $57.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $46.22 | 2025 | |
| Corium, LLC | $34.29 | 2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.26 | 2025 | Relistor, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.82 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $25.84 | 2025 | Ponvory |
| Glaxosmithkline, LLC. | $21.78 | 2024 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $13.72 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.